The applications of animal models in phage therapy: An update

References

• Haq IU, Chaudhry WN, Akhtar MN, Andleeb S, Qadri I. Bacteriophages and their implications on future biotechnology: a review. Virol J. 2012;9(1):1–23. doi:10.1186/1743-422X-9-9.
   PubMedGoogle Scholar
• Brown N, Cox C. Bacteriophage use in molecular biology and biotechnology. Bacterioph Therapy Biol Technol. 2021; 465–506.
   Google Scholar
• Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N. WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar;18(3):318–327. doi:10.1016/S1473-3099(17)30753-3
   Google Scholar
• Srinivasiah S, Bhavsar J, Thapar K, Liles M, Schoenfeld T, Wommack KE. Phages across the biosphere: contrasts of viruses in soil and aquatic environments. Res Microbiol. 2008;159(5):349–57. doi:10.1016/j.resmic.2008.04.010.
   PubMed Web of Science ®Google Scholar
• Oyejobi GK, Sule WF, Akinde SB, Khan FM, Ogolla F. Multidrug-resistant enteric bacteria in Nigeria and potential use of bacteriophages as biocontrol. Sci Total Environ. 2022;824:153842. doi:10.1016/j.scitotenv.2022.153842.
   PubMed Web of Science ®Google Scholar
• Loh B, Gondil VS, Manohar P, Khan FM, Yang H, Leptihn S. Encapsulation and delivery of therapeutic phages. Appl Environ Microbiol. 2021;87(5): e01979-20. doi:10.1128/AEM.01979-20.
   PubMed Web of Science ®Google Scholar
• São-José C, Costa AR, Melo LD. Bacteriophages and their lytic enzymes as alternative antibacterial therapies in the age of antibiotic resistance. Front Microbiol. 2022;13:978. doi:10.3389/fmicb.2022.884176.
   Web of Science ®Google Scholar
• Lin DM, Koskella B, Lin HC. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017;8(3):162. doi:10.4292/wjgpt.v8.i3.162.
   PubMedGoogle Scholar
• Pirnay J, Verbeken G, Ceyssens P-J, Huys I, De Vos D, Ameloot C, Fauconnier A. The magistral phage. Viruses. 2018;10(2):64. doi:10.3390/v10020064.
   PubMed Web of Science ®Google Scholar
• Górski A, Międzybrodzki R, Weber-Dąbrowska B, Fortuna W, Letkiewicz S, Rogóż P, Jończyk-Matysiak E, Dąbrowska K, Majewska J, Borysowski J. Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front Microbiol. 2016;7:1515. doi:10.3389/fmicb.2016.01515.
   PubMed Web of Science ®Google Scholar
• Henein A. What are the limitations on the wider therapeutic use of phage? Bacteriophage. 2013;3(2):e24872. doi:10.4161/bact.24872.
   PubMedGoogle Scholar
• Pouillot F, Chomton M, Blois H, Courroux C, Noelig J, Bidet P, Bingen E, Bonacorsi S. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b: h4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother. 2012;56(7):3568–75. doi:10.1128/AAC.06330-11.
   PubMed Web of Science ®Google Scholar
• Uchiyama J, Rashel M, Takemura I, Wakiguchi H, Matsuzaki S. In silico and in vivo evaluation of bacteriophage φEF24C, a candidate for treatment of Enterococcus faecalis infections. Appl Environ Microbiol. 2008;74(13):4149–63. doi:10.1128/AEM.02371-07.
   PubMed Web of Science ®Google Scholar
• Shivshetty N, Hosamani R, Ahmed L, Oli AK, Sannauallah S, Sharanbassappa S, Patil SA, Kelmani CR. Experimental protection of diabetic mice against Lethal P. aeruginosa infection by bacteriophage. Biomed Res Int. 2014;2014: 793242. doi:10.1155/2014/793242.
   Google Scholar
• Ochieng’oduor JM, Onkoba N, Maloba F, Arodi WO, Nyachieo A. Efficacy of lytic Staphylococcus aureus bacteriophage against multidrug-resistant Staphylococcus aureus in mice. J Infect Dev Ctries. 2016;10(11):1208–13. doi:10.3855/jidc.7931.
   PubMed Web of Science ®Google Scholar
• Chen Y, Guo G, Sun E, Song J, Yang L, Zhu L, Liang W, Hua L, Peng Z, Tang X, et al. Isolation of a T7-like lytic Pasteurella bacteriophage vB_pmup_phb01 and its potential use in therapy against Pasteurella multocida infections. Viruses. 2019;11(1):86. 10.3390/v11010086.
   PubMed Web of Science ®Google Scholar
• Sarker SA, Sultana S, Reuteler G, Moine D, Descombes P, Charton F, Bourdin G, McCallin S, Ngom-Bru C, Neville T, Akter M, Huq S, Qadri F, Talukdar K, Kassam M, Delley M, Loiseau C, Deng Y, El Aidy S, Berger B, Brüssow H. Oral phage therapy of acute bacterial diarrhea tith cwo poliphage Preparations: arandomized trial in children from Bangladesh. EBioMedicine. 2016 Jan 5;4:124–37. doi:10.1016/j.ebiom.2015.12.023.
   PubMed Web of Science ®Google Scholar
• Gindin M, Febvre HP, Rao S, Wallace TC, Weir TL. Bacteriophage for gastrointestinal health (PHAGE) study: evaluating the safety and tolerability of supplemental bacteriophage consumption. J Am Coll Nutr. 2019;38(1):68–75. doi:10.1080/07315724.2018.1483783.
   PubMed Web of Science ®Google Scholar
• Ooi ML, Drilling AJ, Morales S, Fong S, Moraitis S, Macias-Valle L, Vreugde S, Psaltis AJ, Wormald P-J. Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to Staphylococcus aureus. JAMA Otolaryngol–Head Neck Surg. 2019;145(8):723–29. doi:10.1001/jamaoto.2019.1191.
   PubMed Web of Science ®Google Scholar
• Petrovic Fabijan A, Lin RCY, Ho J, Maddocks S, Ben Zakour NL, Iredell JR, Khalid A, Venturini C, Chard R, Morales S, et al. Westmead Bacteriophage Therapy Team. 2020. Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nat Microbiol. 2020;5(3):465–72. doi:10.1038/s41564-019-0634-z.
   PubMed Web of Science ®Google Scholar
• Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW, Schmidt MG, Norris JS. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother. 2003;47(4):1301–07. doi:10.1128/AAC.47.4.1301-1307.2003.
   PubMed Web of Science ®Google Scholar
• Łusiak-Szelachowska M, Żaczek M, Weber-Dabrowska B, Międzybrodzki R, Kłak M, Fortuna W, Letkiewicz S, Rogóż P, Szufnarowski K, Jończyk-Matysiak E, et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 2014;27(6):295–304. doi:10.1089/vim.2013.0128.
   PubMed Web of Science ®Google Scholar
• Speck P, Smithyman A, Millard A. Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett. 2016;363(3):fnv242. doi:10.1093/femsle/fnv242.
   PubMed Web of Science ®Google Scholar
• Żaczek M, Łusiak-Szelachowska M, Jończyk-Matysiak E, Weber-Dąbrowska B, Międzybrodzki R, Owczarek B, Kopciuch A, Fortuna W, Rogóż P, Górski A. Antibody production in response to staphylococcal MS-1 phage cocktail in patients undergoing phage therapy. Front Microbiol. 2016;7:1681. doi:10.3389/fmicb.2016.01681.
   PubMed Web of Science ®Google Scholar
• Roach DR, Debarbieux L. Phage therapy: awakening a sleeping giant. Emerg Top Life Sci. 2017;1(1):93–103. doi:10.1042/ETLS20170002.
   PubMedGoogle Scholar
• Abedon ST. Bacteriophage clinical use as antibacterial “drugs”: utility and precedent. Microbiol Spectr. 2017 Aug;5(4). doi:10.1128/microbiolspec.BAD-0003-2016.
   Google Scholar
• Gondil VS, Chhibber S. Evading antibody mediated inactivation of bacteriophages using delivery systems. J Virol Curr Res. 2017;1:555–74. doi:10.19080/JOJIV.2017.01.555574.
   Google Scholar
• Lu TK, Koeris MS. The next generation of bacteriophage therapy. Current opinion in microbiology. 2011;14(5):524–31. doi:10.1016/j.mib.2011.07.028.
   PubMed Web of Science ®Google Scholar
• Azam AH, Tanji Y. Peculiarities of Staphylococcus aureus phages and their possible application in phage therapy. Appl Microbiol Biotechnol. 2019;103(11):4279–89. doi:10.1007/s00253-019-09810-2.
   PubMed Web of Science ®Google Scholar
• Moller AG, Lindsay JA, Read TD. Determinants of phage host range in Staphylococcus species. Appl Environ Microbiol. 2019;85(11):e00209–19. doi:10.1128/AEM.00209-19.
   PubMed Web of Science ®Google Scholar
• Kishor C, Mishra R, Saraf S, Kumar M, Srivastav A, Nath G. Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model. Indian J Med Res. 2016;143(1):87. doi:10.4103/0971-5916.178615.
   PubMedGoogle Scholar
• Leiman PG, Kanamaru S, Mesyanzhinov VV, Arisaka F, Rossmann MG. Structure and morphogenesis of bacteriophage T4. Cell Mol Life Sci. 2003;60(11):2356–70. doi:10.1007/s00018-003-3072-1.
   PubMed Web of Science ®Google Scholar
• Abatángelo V, Peressutti Bacci N, Boncompain CA, Amadio AA, Carrasco S, Suárez CA, Morbidoni HR. Broad-range lytic bacteriophages that kill Staphylococcus aureus local field strains. PloS One. 2017;12(7):e0181671. doi:10.1371/journal.pone.0181671.
   PubMed Web of Science ®Google Scholar
• Cooper CJ, Koonjan S, Nilsson AS. Enhancing whole phage therapy and their derived antimicrobial enzymes through complex formulation. Pharmaceuticals. 2018;11(2):34. doi:10.3390/ph11020034.
   Web of Science ®Google Scholar
• Lehman SM, Mearns G, Rankin D, Cole R, Smrekar F, Branston S, Morales S. Design and preclinical development of a phage product for the treatment of antibiotic-resistant Staphylococcus aureus infections. Viruses. 2019;11(1):88. doi:10.3390/v11010088.
   PubMed Web of Science ®Google Scholar
• Peng C, Hanawa T, Azam AH, LeBlanc C, Ung P, Matsuda T, Onishi H, Miyanaga K, Tanji Y. Silviavirus phage ɸMR003 displays a broad host range against methicillin-resistant Staphylococcus aureus of human origin. Appl Microbiol Biotechnol. 2019;103(18):7751–65. doi:10.1007/s00253-019-10039-2.
   PubMed Web of Science ®Google Scholar
• Delisle AL, Guo M, Chalmers NI, Barcak GJ, Rousseau GM, Moineau S. Biology and genome sequence of Streptococcus mutans phage M102AD. Appl Environ Microbiol. 2012;78(7):2264–71. doi:10.1128/AEM.07726-11.
   PubMed Web of Science ®Google Scholar
• Bai Q, Zhang W, Yang Y, Tang F, Nguyen X, Liu G, Lu C. Characterization and genome sequencing of a novel bacteriophage infecting Streptococcus agalactiae with high similarity to a phage from Streptococcus pyogenes. Arch Virol. 2013;158(8):1733–41. doi:10.1007/s00705-013-1667-x.
   PubMed Web of Science ®Google Scholar
• Leprohon P, Gingras H, Ouennane S, Moineau S, Ouellette M. A genomic approach to understand interactions between Streptococcus pneumoniae and its bacteriophages. BMC Genomics. 2015;16(1):1–13. doi:10.1186/s12864-015-2134-8.
   PubMedGoogle Scholar
• Witold K, Sabri M, Gingras H, Ouellette M, Tremblay DM, Moineau S. Complete Genome Sequence of Streptococcus pneumoniae Virulent Phage MS1. Microbiol Resour Announc. 2017;5(28). doi:10.1128/genomeA.00333-17.
   Google Scholar
• McDonnell B, Mahony J, Hanemaaijer L, Neve H, Noben J-P, Lugli GA, Ventura M, Kouwen TR, van Sinderen D. Global survey and genome exploration of bacteriophages infecting the lactic acid bacterium Streptococcus thermophilus. Front Microbiol. 2017;8:1754. doi:10.3389/fmicb.2017.01754.
   PubMed Web of Science ®Google Scholar
• McShan WM, McCullor KA, Nguyen SV, Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Braunstein M, Rood JI. The bacteriophages of Streptococcus pyogenes. Microbiol Spectrum. 2019;7(3):7.3. 8. doi:10.1128/microbiolspec.GPP3-0059-2018.
   PubMed Web of Science ®Google Scholar
• Duerkop BA, Palmer KL, Horsburgh MJ. Enterococcal bacteriophages and genome defense. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Enterococci: From commensals to leading causes of drug resistant infection [Internet]. Boston: Massachusetts Eye and Ear Infirmary; 2014 Feb 11.
   Google Scholar
• Khalifa L, Gelman D, Shlezinger M, Dessal AL, Coppenhagen-Glazer S, Beyth N, Hazan R. Defeating antibiotic-and phage-resistant Enterococcus faecalis using a phage cocktail in vitro and in a clot model. Front Microbiol. 2018;9:326. doi:10.3389/fmicb.2018.00326.
   PubMed Web of Science ®Google Scholar
• Lee D, Im J, Na H, Ryu S, Yun C-H, Han SH. The novel Enterococcus phage vB_EfaS_HEf13 has broad lytic activity against clinical isolates of Enterococcus faecalis. Front Microbiol. 2019;10:2877. doi:10.3389/fmicb.2019.02877.
   PubMed Web of Science ®Google Scholar
• Melo LD, Ferreira R, Costa AR, Oliveira H, Azeredo J. Efficacy and safety assessment of two enterococci phages in an in vitro biofilm wound model. Sci Rep. 2019;9(1):1–12. doi:10.1038/s41598-019-43115-8.
   PubMedGoogle Scholar
• Yuan Y, Zhao F, Wang L, Tan D, Cong C, Li X, Xu Y. Complete genome analysis of the novel Enterococcus faecalis phage vB_efas_al3. Arch Virol. 2019;164(10):2599–603. doi:10.1007/s00705-019-04341-7
   PubMed Web of Science ®Google Scholar
• Alkalay S, Sternberg S, Coppenhagen-Glazer S, Hazan R. Complete genome sequences of three bacillus anthracis bacteriophages. Genome Announc. 2018 Jan 4;6(1):e01164–17. doi:10.1128/genomeA.01164-17.
   PubMedGoogle Scholar
• Peng Q, Yuan Y. Characterization of a novel phage infecting the pathogenic multidrug-resistant Bacillus cereus and functional analysis of its endolysin. Appl Microbiol Biotechnol. 2018;102(18):7901–12. doi:10.1007/s00253-018-9219-7.
   PubMed Web of Science ®Google Scholar
• Morris JL, Letson HL, Elliott L, Grant AL, Wilkinson M, Hazratwala K, McEwen P. Evaluation of bacteriophage as an adjunct therapy for treatment of peri-prosthetic joint infection caused by Staphylococcus aureus. PloS One. 2019;14(12):e0226574. doi:10.1371/journal.pone.0226574.
   PubMed Web of Science ®Google Scholar
• Chhibber S, Shukla A, Kaur S. Transfersomal phage cocktail is an effective treatment against methicillin-resistant Staphylococcus aureus-mediated skin and soft tissue infections. Antimicrob Agents Chemother. 2017;61(10): e02146-16. doi:10.1128/AAC.02146-16.
   Web of Science ®Google Scholar
• Geng H, Zou W, Zhang M, Xu L, Liu F, Li X, Wang L, Xu Y. Evaluation of phage therapy in the treatment of Staphylococcus aureus-induced mastitis in mice. Folia Microbiol (Praha). 2020;65(2):339–51. doi:10.1007/s12223-019-00729-9.
   PubMed Web of Science ®Google Scholar
• Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother. 2007;51(8):2765–73. doi:10.1128/AAC.01513-06.
   PubMed Web of Science ®Google Scholar
• Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman M, et al. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage φMR11. J Infect Dis. 2003;187(4):613–24. doi:10.1086/374001.
   PubMed Web of Science ®Google Scholar
• Hsieh SE, Lo HH, Chen ST, Lee MC, Tseng YH. Wide host range and strong lytic activity of Staphylococcus aureus lytic phage Stau2. Appl Environ Microbiol. 2011 Feb;77(3):756–61. doi:10.1128/AEM.01848-10.
   PubMed Web of Science ®Google Scholar
• Takemura-Uchiyama I, Uchiyama J, Osanai M, Morimoto N, Asagiri T, Ujihara T, Daibata M, Sugiura T, Matsuzaki S. Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice. Microb Infect. 2014;16(6):512–17. doi:10.1016/j.micinf.2014.02.011.
   PubMed Web of Science ®Google Scholar
• Almaghrabi MK. Isolation and characterisation of bacteriophages that infect capsulated Streptococcus pneumonia [Thesis]. University of Leicester; 2013. https://hdl.handle.net/2381/28085
   Google Scholar
• Shlezinger M, Friedman M, Houri-Haddad Y, Hazan R, Beyth N. Phages in a thermoreversible sustained-release formulation targeting E. faecalis in vitro and in vivo. PloS One. 2019;14(7):e0219599. doi:10.1371/journal.pone.0219599.
   PubMed Web of Science ®Google Scholar
• Gelman D, Beyth S, Lerer V, Adler K, Poradosu-Cohen R, Coppenhagen-Glazer S, Hazan R. Combined bacteriophages and antibiotics as an efficient therapy against VRE Enterococcus faecalis in a mouse model. Res Microbiol. 2018;169(9):531–39. doi:10.1016/j.resmic.2018.04.008.
   PubMed Web of Science ®Google Scholar
• Manohar P, Shanthini T, Ayyanar R, Bozdogan B, Wilson A, Tamhankar AJ, Nachimuthu R, Lopes BS. The distribution of carbapenem-and colistin-resistance in Gram-negative bacteria from the Tamil Nadu region in India. J Med Microbiol. 2017;66(7):874–83. doi:10.1099/jmm.0.000508.
   PubMed Web of Science ®Google Scholar
• Shiley JR, Comfort KK, Robinson JB. Immunogenicity and antimicrobial effectiveness of Pseudomonas aeruginosa specific bacteriophage in a human lung in vitro model. Appl Microbiol Biotechnol. 2017;101(21):7977–85. doi:10.1007/s00253-017-8504-1.
   PubMed Web of Science ®Google Scholar
• Fong SA, Drilling A, Morales S, Cornet ME, Woodworth BA, Fokkens WJ, Psaltis AJ, Vreugde S, Wormald P-J. Activity of bacteriophages in removing biofilms of Pseudomonas aeruginosa isolates from chronic rhinosinusitis patients. Front Cell Infect Microbiol. 2017;7:418. doi:10.3389/fcimb.2017.00418.
   PubMed Web of Science ®Google Scholar
• Waters EM, Neill DR, Kaman B, Sahota JS, Clokie MRJ, Winstanley C, Kadioglu A. Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax. 2017;72(7):666–67. doi:10.1136/thoraxjnl-2016-209265.
   PubMed Web of Science ®Google Scholar
• Shafique M, Alvi IA, Abbas Z, Ur Rehman S. Assessment of biofilm removal capacity of a broad host range bacteriophage JHP against Pseudomonas aeruginosa. Apmis. 2017;125(6):579–84. doi:10.1111/apm.12691.
   PubMed Web of Science ®Google Scholar
• Alvi IA, Asif M, Tabassum R, Aslam R, Abbas Z, Rehman SU. RLP, a bacteriophage of the family Podoviridae, rescues mice from bacteremia caused by multi-drug-resistant Pseudomonas aeruginosa. Arch Virol. 2020;165(6):1289–97. doi:10.1007/s00705-020-04601-x
   PubMed Web of Science ®Google Scholar
• Pabary R, Singh C, Morales S, Bush A, Alshafi K, Bilton D, Alton EWFW, Smithyman A, Davies JC. Antipseudomonal bacteriophage reduces infective burden and inflammatory response in murine lung. Antimicrob Agents Chemother. 2016;60(2):744–51. doi:10.1128/AAC.01426-15.
   PubMed Web of Science ®Google Scholar
• Tkhilaishvili T, Winkler T, Müller M, Perka C, Trampuz A. Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;64(1): e00924-19. doi:10.1128/AAC.00924-19.
   PubMed Web of Science ®Google Scholar
• Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health. 2018;2018(1):60–66. doi:10.1093/emph/eoy005.
   PubMed Web of Science ®Google Scholar
• Ong SP, Azam AH, Sasahara T, Miyanaga K, Tanji Y. Characterization of Pseudomonas lytic phages and their application as a cocktail with antibiotics in controlling Pseudomonas aeruginosa. J Biosci Bioeng. 2020;129(6):693–99. doi:10.1016/j.jbiosc.2020.02.001.
   PubMed Web of Science ®Google Scholar
• Kusradze I, Karumidze N, Rigvava S, Dvalidze T, Katsitadze M, Amiranashvili I, Goderdzishvili M. Characterization and testing the efficiency of Acinetobacter baumannii phage vB-GEC_Ab-M-G7 as an antibacterial agent. Front Microbiol. 2016;7:1590. doi:10.3389/fmicb.2016.01590.
   PubMed Web of Science ®Google Scholar
• Regeimbal JM, Jacobs AC, Corey BW, Henry MS, Thompson MG, Pavlicek RL, Quinones J, Hannah RM, Ghebremedhin M, Crane NJ, et al. Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob Agents Chemother. 2016;60(10):5806–16. doi:10.1128/AAC.02877-15.
   PubMed Web of Science ®Google Scholar
• Hua Y, Luo T, Yang Y, Dong D, Wang R, Wang Y, Xu M, Guo X, Hu F, He P. Phage therapy as a promising new treatment for lung infection caused by carbapenem-resistant Acinetobacter baumannii in mice. Front Microbiol. 2018;8:2659. doi:10.3389/fmicb.2017.02659.
   PubMed Web of Science ®Google Scholar
• Zhou W, Feng Y, Zong Z. Two new lytic bacteriophages of the Myoviridae family against carbapenem-resistant Acinetobacter baumannii. Front Microbiol. 2018;9:850. doi:10.3389/fmicb.2018.00850.
   PubMed Web of Science ®Google Scholar
• Yin S, Huang G, Zhang Y, Jiang B, Yang Z, Dong Z, You B, Yuan Z, Hu F, Zhao Y, et al. Phage Abp1 rescues human cells and mice from infection by pan-drug resistant Acinetobacter baumannii. Cell Physiol Biochem. 2017;44(6):2337–45. doi:10.1159/000486117.
   PubMedGoogle Scholar
• Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017;61(10): e00954-17. doi: 10.1128/AAC.00954-17.
   PubMed Web of Science ®Google Scholar
• Kumari S, Harjai K, Chhibber S. Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. J Med Microbiol. 2011;60(2):205–10. doi:10.1099/jmm.0.018580-0.
   PubMed Web of Science ®Google Scholar
• Manohar P, Nachimuthu R, Lopes BS. The therapeutic potential of bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model. BMC Microbiol. 2018;18(1):1–11. doi:10.1186/s12866-018-1234-4.
   PubMedGoogle Scholar
• Hsieh SE, Lo HH, Chen ST, Lee MC, Tseng YH. Wide host range and strong lytic activity of Staphylococcus aureus lytic phage Stau2. Appl Environ Microbiol. 2011 Feb;77(3):756–61. doi:10.1128/AEM.01848-10.
   PubMed Web of Science ®Google Scholar
• Dufour N, Debarbieux L, Fromentin M, Ricard J-D. Treatment of highly virulent extraintestinal pathogenic Escherichia coli pneumonia with bacteriophages. Crit Care Med. 2015;43(6):e190–98. doi:10.1097/CCM.0000000000000968.
   PubMed Web of Science ®Google Scholar
• Kaabi SAG, Musafer HK. An experimental mouse model for phage therapy of bacterial pathogens causing bacteremia. Microb Pathog. 2019;137:103770. doi:10.1016/j.micpath.2019.103770.
   PubMed Web of Science ®Google Scholar
• Matsushita K, Uchiyama J, Kato S-I, Ujihara T, Hoshiba H, Sugihara S, Muraoka A, Wakiguchi H, Matsuzaki S. Morphological and genetic analysis of three bacteriophages of Serratia marcescens isolated from environmental water. FEMS Microbiol Lett. 2009;291(2):201–08. doi:10.1111/j.1574-6968.2008.01455.x.
   PubMed Web of Science ®Google Scholar
• Mai V, Ukhanova M, Reinhard MK, Li M, Sulakvelidze A. Bacteriophage administration significantly reduces Shigella colonization and shedding by Shigella-challenged mice without deleterious side effects and distortions in the gut microbiota. Bacteriophage. 2015;5(4):e1088124. doi:10.1080/21597081.2015.1088124.
   PubMedGoogle Scholar
• Alves DR, Nzakizwanayo J, Dedi C, Olympiou C, Hanin A, Kot W, Hansen L, Lametsch R, Gahan CGM, Schellenberger P, et al. Genomic and ecogenomic characterization of Proteus mirabilis bacteriophages. Front Microbiol. 2019;10:1783. doi:10.3389/fmicb.2019.01783.
   PubMed Web of Science ®Google Scholar
• Dallal MMS, Nikkhahi F, Alimohammadi M, Douraghi M, Rajabi Z, Foroushani AR, Azimi A, Fardsanei F. Phage therapy as an approach to control Salmonella enterica serotype enteritidis infection in mice. Rev Soc Bras Med Trop. 2019;52:e20190290. doi:10.1590/0037-8682-0290-2019.
   PubMed Web of Science ®Google Scholar
• Chang RYK, Chen K, Wang J, Wallin M, Britton W, Morales S, Kutter E, Li J, Chan H-K. Proof-of-principle study in a murine lung infection model of antipseudomonal activity of phage PEV20 in a dry-powder formulation. Antimicrob Agents Chemother. 2018;62(2):e01714–17. doi:10.1128/AAC.01714-17.
   PubMed Web of Science ®Google Scholar
• Forti F, Roach DR, Cafora M, Pasini ME, Horner DS, Fiscarelli EV, Rossitto M, Cariani L, Briani F, Debarbieux L, et al. Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa biofilms and treats acute infections in two animal models. Antimicrob Agents Chemother. 2018;62(6):e02573–17 doi: 10.1128/AAC.02573-17.
   PubMed Web of Science ®Google Scholar
• Fukuda K, Ishida W, Uchiyama J, Rashel M, Kato S-I, Morita T, Muraoka A, Sumi T, Matsuzaki S, Daibata M, et al. Pseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administration. PloS One. 2012;7(10):e47742. doi:10.1371/journal.pone.0047742.
   PubMed Web of Science ®Google Scholar
• Schneider G, Szentes N, Horváth M, Dorn Á, Cox A, Nagy G, Doffkay Z, Maróti G, Rákhely G, Kovács T. Kinetics of targeted phage rescue in a mouse model of systemic Escherichia coli K1. Biomed Res Int. 2018;2018:2018. doi:10.1155/2018/7569645.
   Web of Science ®Google Scholar
• Brix A, Cafora M, Aureli M, Pistocchi A. Animal models to translate phage therapy to human medicine. Int J Mol Sci. 2020;21(10):3715. doi:10.3390/ijms21103715.
   PubMed Web of Science ®Google Scholar
• Augustine J, Gopalakrishnan MV, Bhat SG. Application of ΦSP-1 and ΦSP-3 as a therapeutic strategy against Salmonella Enteritidis infection using Caenorhabditis elegans as model organism. FEMS Microbiol Lett. 2014;356(1):113–17. doi:10.1111/1574-6968.12493.
   PubMed Web of Science ®Google Scholar
• Głowacka-Rutkowska A, Gozdek A, Empel J, Gawor J, Żuchniewicz K, Kozińska A, Dębski J, Gromadka R, Łobocka M. The ability of lytic staphylococcal podovirus vB_saup_phiago1. 3 to coexist in equilibrium with its host facilitates the selection of host mutants of attenuated virulence but does not preclude the phage antistaphylococcal activity in a nematode infection model. Front Microbiol. 2018;9:3227. doi:10.3389/fmicb.2018.03227.
   PubMed Web of Science ®Google Scholar
• Buchon N, Silverman N, Cherry S. Immunity in Drosophila melanogaster—from microbial recognition to whole-organism physiology. Nat Rev Immunol. 2014;14(12):796–810. doi:10.1038/nri3763.
   PubMed Web of Science ®Google Scholar
• Lindberg HM, McKean KA, Wang I-N. Phage fitness may help predict phage therapy efficacy. Bacteriophage. 2014;4(4):e964081. 10.4161/21597073.2014.964081
   PubMedGoogle Scholar
• Cao F, Wang X, Wang L, Li Z, Che J, Wang L, Li X, Cao Z, Zhang J, Jin L, Xu Y. Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. Biomed Res Int. 2015;2015:752930. doi:10.1155/2015/752930.
   PubMed Web of Science ®Google Scholar
• Heo YJ, Lee YR, Jung HH, Lee J, Ko G, Cho YH. Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob Agents Chemother. 2009 Jun;53(6):2469–74. doi:10.1128/AAC.01646-08.
   PubMed Web of Science ®Google Scholar
• Seed KD, Dennis JJ. Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex. Antimicrob Agents Chemother. 2009;53(5):2205–08. doi:10.1128/AAC.01166-08.
   PubMed Web of Science ®Google Scholar
• Nale JY, Chutia M, Carr P, Hickenbotham PT, Clokie MRJ. ‘Get in early’; biofilm and wax moth (Galleria mellonella) models reveal new insights into the therapeutic potential of Clostridium difficile bacteriophages. Front Microbiol. 2016;7:1383. doi:10.3389/fmicb.2016.01383.
   PubMed Web of Science ®Google Scholar
• Neely MN, Pfeifer JD, Caparon M. Streptococcus-zebrafish model of bacterial pathogenesis. Infect Immun. 2002;70(7):3904–14. doi:10.1128/IAI.70.7.3904-3914.2002.
   PubMed Web of Science ®Google Scholar
• Al-Zubidi M, Widziolek M, Court EK, Gains AF, Smith RE, Ansbro K, Alrafaie A, Evans C, Murdoch C, Mesnage S, et al. Identification of novel bacteriophages with therapeutic potential that target Enterococcus faecalis. Infect Immun. 2019;87(11):512–19. doi:10.1128/IAI.00512-19.
   Web of Science ®Google Scholar
• Cafora M, Deflorian G, Forti F, Ferrari L, Binelli G, Briani F, Ghisotti D, Pistocchi A. Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model. Sci Rep. 2019;9(1):1527. doi:10.1038/s41598-018-37636-x.
   PubMedGoogle Scholar
• Ahmadi M, Karimi Torshizi MA, Rahimi S, Dennehy JJ. Prophylactic bacteriophage administration more effective than post-infection administration in reducing Salmonella enterica serovar Enteritidis shedding in quail. Front Microbiol. 2016;7:1253. doi:10.3389/fmicb.2016.01253.
   PubMed Web of Science ®Google Scholar
• Wernicki A, Nowaczek A, Urban-Chmiel R. Bacteriophage therapy to combat bacterial infections in poultry. Virol J. 2017;14(1):1–13. doi:10.1186/s12985-017-0849-7.
   PubMedGoogle Scholar
• Colom J, Cano-Sarabia M, Otero J, Aríñez-Soriano J, Cortés P, Maspoch D, Llagostera M. Microencapsulation with alginate/CaCO3: a strategy for improved phage therapy. Sci Rep. 2017;7(1):1–10. doi:10.1038/srep41441.
   PubMedGoogle Scholar
• Colom J, Cano-Sarabia M, Otero J, Cortés P, Maspoch D, Llagostera M. Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp. Appl Environ Microbiol. 2015;81(14):4841–49. doi:10.1128/AEM.00812-15.
   PubMed Web of Science ®Google Scholar
• Waseh S, Hanifi-Moghaddam P, Coleman R, Masotti M, Ryan S, Foss M, MacKenzie R, Henry M, Szymanski CM, Tanha J, et al. Orally administered P22 phage tailspike protein reduces Salmonella colonization in chickens: prospects of a novel therapy against bacterial infections. PloS One. 2010;5(11):e13904. doi:10.1371/journal.pone.0013904.
   PubMed Web of Science ®Google Scholar
• Jang HJ, Bae HW, Cho YH. Exploitation of Drosophila infection models to evaluate antibacterial efficacy of phages. Methods Mol Biol. 2019;1898:183–190. doi:10.1007/978-1-4939-8940-9_15.
   PubMedGoogle Scholar
• Wills QF, Kerrigan C, Soothill JS. Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother. 2005;49(3):1220–21. doi:10.1128/AAC.49.3.1220-1221.2005.
   PubMed Web of Science ®Google Scholar
• Abedon ST. Commentary: phage therapy of staphylococcal chronic osteomyelitis in experimental animal model. Front Microbiol. 2016 Aug 10;7:1251. doi:10.3389/fmicb.2016.01251.
   Web of Science ®Google Scholar
• Yen M, Cairns LS, Camilli A. A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models. Nat Commun. 2017;8(1):1–7. doi:10.1038/ncomms14187.
   PubMedGoogle Scholar
• Nale JY, Spencer J, Hargreaves KR, Buckley AM, Trzepiński P, Douce GR, Clokie MRJ. Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother. 2016;60(2):968–81. doi:10.1128/AAC.01774-15.
   PubMed Web of Science ®Google Scholar
• Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis. 2010;201(7):1096–104. doi:10.1086/651135.
   PubMed Web of Science ®Google Scholar
• Leshkasheli L, Kutateladze M, Balarjishvili N, Bolkvadze D, Save J, Oechslin F, Que Y-A, Resch G. Efficacy of newly isolated and highly potent bacteriophages in a mouse model of extensively drug-resistant Acinetobacter baumannii bacteraemia. J Global Antimicrob Resist. 2019;19:255–61. doi:10.1016/j.jgar.2019.05.005.
   PubMed Web of Science ®Google Scholar
• Melo LD, Oliveira H, Pires DP, Dabrowska K, Azeredo J. Phage therapy efficacy: a review of the last 10 years of preclinical studies. Crit Rev Microbiol. 2020;46(1):78–99. doi:10.1080/1040841X.2020.1729695.
   PubMed Web of Science ®Google Scholar
• Jault P, Leclerc T, Jennes S, Pirnay JP, Que Y-A, Resch G, Rousseau AF, Ravat F, Carsin H, Le Floch R, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19(1):35–45. doi:10.1016/S1473-3099(18)30482-1.
   PubMed Web of Science ®Google Scholar
• Leitner L, Ujmajuridze A, Chanishvili N, Goderdzishvili M, Chkonia I, Rigvava S, Chkhotua A, Changashvili G, McCallin S, Schneider MP, et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021;21(3):427–36. doi:10.1016/S1473-3099(20)30330-3.
   PubMed Web of Science ®Google Scholar
• Srivastava AS, Kaido T, Carrier E. Immunological factors that affect the in vivo fate of T7 phage in the mouse. J Virol Methods. 2004;115(1):99–104. doi:10.1016/j.jviromet.2003.09.009.
   PubMed Web of Science ®Google Scholar
• Jikia D, Chkhaidze N, Imedashvili E, Mgaloblishvili I, Tsitlanadze G, Katsarava R, Glenn Morris J, Sulakvelidze A. The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90. Clin Exp Dermatol: Clin Dermatol. 2005;30(1):23–26. doi:10.1111/j.1365-2230.2004.01600.x.
   PubMed Web of Science ®Google Scholar
• Hatfull GF, Dedrick RM, Schooley RT. Phage therapy for antibiotic-resistant bacterial infections. Annu Rev Med. 2022;73(1):197–211. doi:10.1146/annurev-med-080219-122208.
   PubMedGoogle Scholar
• Petrovic Fabijan A, Lin RCY, Ho J, Maddocks S, Ben Zakour NL, Iredell JR, Khalid A, Venturini C, Chard R, Morales S, et al. Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nat Microbiol. 2020;5(3):465–72. doi:10.1038/s41564-019-0634-z.
   PubMed Web of Science ®Google Scholar
• Schooley RT, Strathdee S. Treat phage like living antibiotics. Nat Microbiol. 2020;5(3):391–92. doi:10.1038/s41564-019-0666-4.
   PubMed Web of Science ®Google Scholar
• Van Nieuwenhuyse B, Van der Linden D, Chatzis O, Lood C, Wagemans J, Lavigne R, Schroven K, Paeshuyse J, de Magnée C, Sokal E, et al. Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler. Nat Commun. 2022;13(1):5725. doi:10.1038/s41467-022-33294-w.
   PubMed Web of Science ®Google Scholar
• Tan X, Chen H, Zhang M, Zhao Y, Jiang Y, Liu X, Huang W, Ma Y. Clinical experience of personalized phage therapy against carbapenem-resistant Acinetobacter baumannii lung infection in a patient with chronic obstructive pulmonary disease. Front Cell Infect Microbiol. 2021;11:631585. doi:10.3389/fcimb.2021.631585.
   PubMed Web of Science ®Google Scholar
• Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, Gilmour KC, Soothill J, Jacobs-Sera D, Schooley RT, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25(5):730–33. doi:10.1038/s41591-019-0437-z.
   PubMed Web of Science ®Google Scholar
• Little JS, Dedrick RM, Freeman KG, Cristinziano M, Smith BE, Benson CA, Jhaveri TA, Baden LR, Solomon DA, Hatfull GF. Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection. Nat Commun. 2022;13(1):1–7. doi:10.1038/s41467-022-29689-4.
   PubMed Web of Science ®Google Scholar
• Llamas MA, van der Sar AM. Assessing Pseudomonas virulence with nonmammalian host: zebrafish. Methods Mol Biol. 2014;1149:709–21. doi:10.1007/978-1-4939-0473-0_55.
   PubMedGoogle Scholar
• Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon S. Phage therapy in clinical practice: treatment of human infections. curr Pharmac Biotechnol. 2010;11(1):69–86. doi:10.2174/138920110790725401.
   PubMed Web of Science ®Google Scholar
• Roach DR, Leung CY, Henry M, Morello E, Singh D, Di Santo JP, Weitz JS, Debarbieux L. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe. 2017;22(1):38–47. e4. doi:10.1016/j.chom.2017.06.018.
   PubMed Web of Science ®Google Scholar
• Wright A, Hawkins CH, Änggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa ; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349–57. doi:10.1111/j.1749-4486.2009.01973.x.
   PubMed Web of Science ®Google Scholar
• Rhoads D, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009;18(6):237–43. doi:10.12968/jowc.2009.18.6.42801.
   PubMedGoogle Scholar
• Dąbrowska K, Miernikiewicz P, Piotrowicz A, Hodyra K, Owczarek B, Lecion D, Kaźmierczak Z, Letarov A, Górski A. Immunogenicity studies of proteins forming the T4 phage head surface. J Virol. 2014;88(21):12551–57. doi:10.1128/JVI.02043-14.
   PubMed Web of Science ®Google Scholar
• Stacey HJ, De Soir S, Jones JD. The safety and efficacy of phage therapy: a systematic review of clinical and safety trials. Antibiotics. 2022;11(10):1340. doi:10.3390/antibiotics11101340.
   Google Scholar
• Suh GA, Lodise TP, Tamma PD, Knisely JM, Alexander J, Aslam S, Barton KD, Bizzell E, Totten KMC, Campbell JL, et al. Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrob Agents Chemother. 2022;66(3): e02071-21 doi: 10.1128/aac.02071-21.
   PubMed Web of Science ®Google Scholar
• Uyttebroek S, Chen B, Onsea J, Ruythooren F, Debaveye Y, Devolder D, Spriet I, Depypere M, Wagemans J, Lavigne R, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 2022;22(8):e208–20. doi:10.1016/S1473-3099(21)00612-5.
   PubMed Web of Science ®Google Scholar
• Nick JA, Dedrick RM, Gray AL, Vladar EK, Smith BE, Freeman KG, Malcolm KC, Epperson LE, Hasan NA, Hendrix J, Callahan K, Walton K, Vestal B, Wheeler E, Rysavy NM, Poch K, Caceres S, Lovell VK, Hisert KB, de Moura VC, Chatterjee D, De P, Weakly N, Martiniano SL, Lynch DA, Daley CL, Strong M, Jia F, Hatfull GF, Davidson RM. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022 May 26;185(11):1860–1874.e12. doi:10.1016/j.cell.2022.04.024.
   Google Scholar
• Lin J, Du F, Long M, Li P. Limitations of phage therapy and corresponding optimization strategies: a review. Molecules. 2022;27(6):1857. doi:10.3390/molecules27061857.
   PubMed Web of Science ®Google Scholar
• Gill JJ, Hyman P. Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol. 2010;11(1):2–14. doi:10.2174/138920110790725311.
   PubMed Web of Science ®Google Scholar
• Carascal MB, Dela Cruz-Papa DM, Remenyi R, Cruz MCB, Destura RV. Phage revolution against multidrug-resistant clinical pathogens in Southeast Asia. Front Microbiol. 2022;13:34. doi:10.3389/fmicb.2022.820572.
   Google Scholar
• Tsonos J, Vandenheuvel D, Briers Y, De Greve H, Hernalsteens J-P, Lavigne R. Hurdles in bacteriophage therapy: deconstructing the parameters. Vet Microbiol. 2014;171(3–4):460–69. doi:10.1016/j.vetmic.2013.11.001.
   PubMed Web of Science ®Google Scholar
• Fauconnier A. Phage therapy regulation: from night to dawn. Viruses. 2019;11(4):352. 10.3390/v11040352
   PubMed Web of Science ®Google Scholar
• Verbeken G, Pirnay J-P, Lavigne R, Jennes S, De Vos D, Casteels M, Huys I. Call for a dedicated European legal framework for bacteriophage therapy. Arch Immunol Ther Exp (Warsz). 2014;62(2):117–29. doi:10.1007/s00005-014-0269-y.
   PubMed Web of Science ®Google Scholar
• Oechslin F. Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy. Viruses. 2018;10(7):351. doi:10.3390/v10070351.
   PubMed Web of Science ®Google Scholar
• Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol. 2010;70:217–48.
   PubMed Web of Science ®Google Scholar
• Rath D, Amlinger L, Rath A, Lundgren M. The CRISPR-Cas immune system: biology, mechanisms and applications. Biochimie. 2015;117:119–28. doi:10.1016/j.biochi.2015.03.025.
   PubMed Web of Science ®Google Scholar
• Deveau H, Garneau JE, Moineau S. CRISPR/Cas system and its role in phage-bacteria interactions. Annu Rev Microbiol. 2010;64(1):475–93. doi:10.1146/annurev.micro.112408.134123.
   PubMedGoogle Scholar
• Merril CR. Interaction of bacteriophages with animals. Cambridge, UK: Cambridge University Press; 2008. p. 332–52.
   Google Scholar
• Gill J, Pacan JC, Carson ME, Leslie KE, Griffiths MW, Sabour PM. Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle. Antimicrob Agents Chemother. 2006;50(9):2912–18. doi:10.1128/AAC.01630-05.
   PubMed Web of Science ®Google Scholar
• Zelasko S, Gorski A, Dabrowska K. Delivering phage therapy per os: benefits and barriers. Expert Rev Anti Infect Ther. 2017;15(2):167–79. doi:10.1080/14787210.2017.1265447.
   PubMed Web of Science ®Google Scholar
• Huh H, Wong S, St. Jean J, Slavcev R. Bacteriophage interactions with mammalian tissue: therapeutic applications. Adv Drug Deliv Rev. 2019;145:4–17. doi:10.1016/j.addr.2019.01.003.
   PubMed Web of Science ®Google Scholar
• Goodridge LD. Designing phage therapeutics. Curr Pharm Biotechnol. 2010;11(1):15–27. doi:10.2174/138920110790725348.
   PubMed Web of Science ®Google Scholar
• Labrie SJ, Samson JE, Moineau S. Nat Rev Microbiol. 2010;8(5):317–27. 10.1038/nrmicro2315.
   PubMed Web of Science ®Google Scholar
• Park K, Cha K, Myung H. Observation of inflammatory responses in mice orally fed with bacteriophage T 7. J Appl Microbiol. 2014;117(3):627–33. doi:10.1111/jam.12565.
   PubMed Web of Science ®Google Scholar
• Miernikiewicz P, Dąbrowska K, Piotrowicz A, Owczarek B, Wojas-Turek J, Kicielińska J, Rossowska J, Pajtasz-Piasecka E, Hodyra K, Macegoniuk K, et al. T4 phage and its head surface proteins do not stimulate inflammatory mediator production. PloS One. 2013;8(8):e71036. doi:10.1371/journal.pone.0071036.
   PubMed Web of Science ®Google Scholar
• Hwang J-Y, Kim J-E, Song Y-J, Park J-H. Safety of using Escherichia coli bacteriophages as a sanitizing agent based on inflammatory responses in rats. Food Sci Biotechnol. 2016;25(1):355–60. doi:10.1007/s10068-016-0050-6.
   PubMed Web of Science ®Google Scholar
• Carmody LA, Gill J, Summer E, Sajjan U, Gonzalez C, Young R, LiPuma J. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis. 2010;201(2):264–71. doi:10.1086/649227.
   PubMed Web of Science ®Google Scholar
• Kaźmierczak Z, Majewska J, Miernikiewicz P, Międzybrodzki R, Nowak S, Harhala M, Lecion D, Kęska W, Owczarek B, Ciekot J, et al. Immune response to therapeutic staphylococcal bacteriophages in mammals: kinetics of induction, immunogenic structural proteins, natural and induced antibodies. Front Immunol. 2021;12:2073. doi:10.3389/fimmu.2021.639570.
   Web of Science ®Google Scholar
• Van Belleghem JD, Dąbrowska K, Vaneechoutte M, Barr J, Bollyky P. Interactions between bacteriophage, bacteria, and the mammalian immune system. Viruses. 2018;11(1):10. doi:10.3390/v11010010.
   PubMed Web of Science ®Google Scholar
• Balogh B, Jones J, Iriarte F, Momol M. Phage therapy for plant disease control. curr Pharmac Biotechnol. 2010;11(1):48–57. doi:10.2174/138920110790725302.
   PubMed Web of Science ®Google Scholar
• Tetz GV, Ruggles KV, Zhou H, Heguy A, Tsirigos A, Tetz V. Bacteriophages as potential new mammalian pathogens. Sci Rep. 2017;7(1):1–9. doi:10.1038/s41598-017-07278-6.
   PubMedGoogle Scholar
• McVay CS, Velásquez M, Fralick JA. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother. 2007;51(6):1934–38. doi:10.1128/AAC.01028-06.
   PubMed Web of Science ®Google Scholar
• Viscardi M, Perugini AG, Auriemma C, Capuano F, Morabito S, Kim K-P, Loessner MJ, Iovane G. Isolation and characterisation of two novel coliphages with high potential to control antibiotic-resistant pathogenic Escherichia coli (EHEC and EPEC). Int J Antimicrob Agents. 2008;31(2):152–57. doi:10.1016/j.ijantimicag.2007.09.007.
   PubMed Web of Science ®Google Scholar
• Lenneman BR, Fernbach J, Loessner MJ, Lu TK, Kilcher S. Enhancing phage therapy through synthetic biology and genome engineering. Curr Opin Biotechnol. 2021;68:151–59. doi:10.1016/j.copbio.2020.11.003.
   PubMed Web of Science ®Google Scholar
• Yue H, Li Y, Yang M, Mao C. T7 Phage as an Emerging Nanobiomaterial with Genetically Tunable Target Specificity. Adv Sci. 2022;9(4):2103645. doi:10.1002/advs.202103645.
   Web of Science ®Google Scholar
• Omidfar K, Daneshpour M. Advances in phage display technology for drug discovery. Expert Opin Drug Discov. 2015;10(6):651–69. doi:10.1517/17460441.2015.1037738.
   PubMed Web of Science ®Google Scholar
• Peng S-Y, You R-I, Lai M-J, Lin N-T, Chen L-K, Chang K-C. Highly potent antimicrobial modified peptides derived from the Acinetobacter baumannii phage endolysin LysAB2. Sci Rep. 2017;7(1):1–12. doi:10.1038/s41598-017-11832-7.
   PubMedGoogle Scholar
• Pelfrene E, Willebrand E, Cavaleiro Sanches A, Sebris Z, Cavaleri M. Bacteriophage therapy: a regulatory perspective. J Antimicrob Chemother. 2016;71(8):2071–74. doi:10.1093/jac/dkw083.
   PubMed Web of Science ®Google Scholar
• Furfaro LL, Payne MS, Chang BJ. Bacteriophage therapy: clinical trials and regulatory hurdles. Front Cell Infect Microbiol. 2018;8:376. doi:10.3389/fcimb.2018.00376.
   PubMed Web of Science ®Google Scholar
• Luong T, Salabarria A-C, Edwards RA, Roach DR. Standardized bacteriophage purification for personalized phage therapy. Nat Protoc. 2020;15(9):2867–90. doi:10.1038/s41596-020-0346-0.
   PubMed Web of Science ®Google Scholar
• Cui Z, Guo X, Feng T, Li L. Exploring the whole standard operating procedure for phage therapy in clinical practice. J Transl Med. 2019;17(1):1–7. doi:10.1186/s12967-019-2120-z.
   PubMed Web of Science ®Google Scholar
• Morrisette T, Kebriaei R, Lev KL, Morales S, Rybak MJ. Bacteriophage therapeutics: a primer for clinicians on phage-antibiotic combinations. Pharmacotherapy: J Hum Pharmacol Drug Therapy. 2020;40(2):153–68. doi:10.1002/phar.2358.
   Google Scholar
• Oechslin F, Piccardi P, Mancini S, Gabard J, Moreillon P, Entenza JM, Resch G, Que Y-A. Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J Infect Dis. 2017;215(5):703–12. doi:10.1093/infdis/jiw632.
   PubMed Web of Science ®Google Scholar
• Akturk E, Oliveira H, Santos SB, Costa S, Kuyumcu S, Melo LDR, Azeredo J. Synergistic action of phage and antibiotics: parameters to enhance the killing efficacy against mono and dual-species biofilms. Antibiotics. 2019;8(3):103. doi:10.3390/antibiotics8030103.
   Google Scholar
• Gayder S, Parcey M, Nesbitt D, Castle AJ, Svircev AM. Population dynamics between Erwinia amylovora, Pantoea agglomerans and bacteriophages: exploiting synergy and competition to improve phage cocktail efficacy. Microorganisms. 2020;8(9):1449. doi:10.3390/microorganisms8091449.
   PubMed Web of Science ®Google Scholar
• García P, Martínez B, Rodríguez L, Rodríguez A. Synergy between the phage endolysin LysH5 and nisin to kill Staphylococcus aureus in pasteurized milk. Int J Food Microbiol. 2010;141(3):151–55. doi:10.1016/j.ijfoodmicro.2010.04.029.
   PubMed Web of Science ®Google Scholar
• Titze I, Krömker V. Antimicrobial activity of a phage mixture and a lactic acid bacterium against Staphylococcus aureus from bovine mastitis. Vet Sci. 2020;7(1):31. doi:10.3390/vetsci7010031.
   PubMedGoogle Scholar
• Aslam S, Lampley E, Wooten D, Karris M, Benson C, Strathdee S, Schooley RT. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open Forum Infect Dis. 2020 Aug 27 ;7(9):ofaa389. doi:10.1093/ofid/ofaa389.
   Google Scholar
• Vashisth M, Yashveer S, Anand T, Virmani N, Bera BC, Vaid RK. Antibiotics targeting bacterial protein synthesis reduce the lytic activity of bacteriophages. Virus Res. 2022 Nov;321:198909. doi:10.1016/j.virusres.2022.198909.
   PubMed Web of Science ®Google Scholar
• Ma Y, Pacan JC, Wang Q, Xu Y, Huang X, Korenevsky A, Sabour PM. Microencapsulation of bacteriophage Felix O1 into chitosan-alginate microspheres for oral delivery. Appl Environ Microbiol. 2008;74(15):4799–805. doi:10.1128/AEM.00246-08.
   PubMed Web of Science ®Google Scholar
• Dini C, Islan GA, Castro GR. Characterization and stability analysis of biopolymeric matrices designed for phage-controlled release. Appl Biochem Biotechnol. 2014;174(6):2031–47. doi:10.1007/s12010-014-1152-3.
   PubMed Web of Science ®Google Scholar
• Otero J, García-Rodríguez A, Cano-Sarabia M, Maspoch D, Marcos R, Cortés P, Llagostera M. Biodistribution of liposome-encapsulated bacteriophages and their transcytosis during oral phage therapy. Front Microbiol. 2019;10:689. doi:10.3389/fmicb.2019.00689.
   PubMed Web of Science ®Google Scholar
• Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechnol. 2010;11(1):28–47. doi:10.2174/138920110790725410.
   PubMed Web of Science ®Google Scholar
• Kaur P, Gondil VS, Chhibber S. A novel wound dressing consisting of PVA-SA hybrid hydrogel membrane for topical delivery of bacteriophages and antibiotics. Int J Pharm. 2019;572:118779. doi:10.1016/j.ijpharm.2019.118779.
   PubMedGoogle Scholar
• Gondil VS, Chhibber S. Bacteriophage and endolysin encapsulation systems: a promising strategy to improve therapeutic outcomes. Front Pharmacol. 2021;12:675440. doi:10.3389/fphar.2021.675440.
   PubMed Web of Science ®Google Scholar
• Fischetti VA. Development of phage lysins as novel therapeutics: a historical perspective. Viruses. 2018;10(6):310. doi:10.3390/v10060310.
   PubMed Web of Science ®Google Scholar
• Khan FM, Gondil VS, Li C, Jiang M, Li J, Yu J, Wei H, Yang H. A novel Acinetobacter baumannii bacteriophage endolysin LysAB54 with high antibacterial activity against multiple Gram-negative microbes. Front Cell Infect Microbiol. 2021;11:637313. doi:10.3389/fcimb.2021.637313.
   PubMed Web of Science ®Google Scholar
• Li C, Jiang M, Khan FM, Zhao X, Wang G, Zhou W, Li J, Yu J, Li Y, Wei H, et al. Intrinsic antimicrobial peptide facilitates a new broad-spectrum lysin LysP53 to kill Acinetobacter baumannii in vitro and in a mouse burn infection model. ACS Infect Dis. 2021;7(12):3336–44. doi:10.1021/acsinfecdis.1c00497.
   PubMed Web of Science ®Google Scholar
• Waddell TE, Franklin K, Mazzocco A, Johnson RP. Preparation and characterization of anti-phage serum. Methods Mol Biol. 2009;501:287–92. doi:10.1007/978-1-60327-164-6_24.
   PubMedGoogle Scholar
• Abdelrahman F, Easwaran M, Daramola OI, Ragab S, Lynch S, Oduselu TJ, Khan FM, Ayobami A, Adnan F, Torrents E, et al. Phage-encoded endolysins. Antibiotics. 2021;10(2):124. doi:10.3390/antibiotics10020124.
   Google Scholar
• Gondil VS, Harjai K, Chhibber S. Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections. Int J Antimicrob Agents. 2020;55(2):105844. doi:10.1016/j.ijantimicag.2019.11.001.
   PubMed Web of Science ®Google Scholar
• Seijsing J, Sobieraj AM, Keller N, Shen Y, Zinkernagel AS, Loessner MJ, Schmelcher M. Improved biodistribution and extended serum half-life of a bacteriophage endolysin by albumin binding domain fusion. Front Microbiol. 2018;9:2927. doi:10.3389/fmicb.2018.02927.
   PubMed Web of Science ®Google Scholar
• Tagliaferri TL, Jansen M, Horz H-P. Fighting pathogenic bacteria on two fronts: phages and antibiotics as combined strategy. Front Cell Infect Microbiol. 2019;9:22. doi:10.3389/fcimb.2019.00022.
   PubMed Web of Science ®Google Scholar
• Gondil VS, Khan FM, Mehra N, Kumar D, Khullar A, Sharma T, Sharma A, Mehta R, Yang H. Clinical potential of bacteriophage and endolysin based therapeutics: A futuristic approach. In: Arora PK, editor. Microbial products for health, environment and agriculture. Singapore: Springer Singapore; 2021. p. 39–58. doi:10.1007/978-981-16-1947-2_3.
   Google Scholar
• Harhala MA, Gembara K, Nelson DC, Miernikiewicz P, Dąbrowska K. Immunogenicity of Endolysin PlyC. Antibiotics. 2022;11(7):966. doi:10.3390/antibiotics11070966.
   Google Scholar
• Kim S, Lee D-W, Jin J-S, Kim J. Antimicrobial activity of LysSS, a novel phage endolysin, against Acinetobacter baumannii and Pseudomonas aeruginosa. J Global Antimicrob Resist. 2020;22:32–39. doi:10.1016/j.jgar.2020.01.005.
   PubMed Web of Science ®Google Scholar
• Li X, Wang S, Nyaruaba R, Liu H, Yang H, Wei H. A highly active chimeric lysin with a calcium-enhanced bactericidal activity against Staphylococcus aureus in vitro and in vivo. Antibiotics. 2021;10(4):461. doi:10.3390/antibiotics10040461.
   Google Scholar
• Yang H, Zhang Y, Yu J, Huang Y, Zhang X-E, Wei H. Novel chimeric lysin with high-level antimicrobial activity against methicillin-resistant Staphylococcus aureus in vitro and in vivo. Antimicrob Agents Chemother. 2014;58(1):536–42. doi:10.1128/AAC.01793-13.
   PubMed Web of Science ®Google Scholar
• Yang H, Zhang H, Wang J, Yu J, Wei H. A novel chimeric lysin with robust antibacterial activity against planktonic and biofilm methicillin-resistant Staphylococcus aureus. Sci Rep. 2017;7(1):1–13. doi:10.1038/srep40182.
   PubMedGoogle Scholar
• Yang H, Luo D, Etobayeva I, Li X, Gong Y, Wang S, Li Q, Xu P, Yin W, He J, et al. Linker editing of pneumococcal lysin ClyJ conveys improved bactericidal activity. Antimicrob Agents Chemother. 2020;64(2):e01610–19. doi:10.1128/AAC.01610-19.
   PubMed Web of Science ®Google Scholar
• Yang H, Gong Y, Zhang H, Etobayeva I, Miernikiewicz P, Luo D, Li X, Zhang X, Dąbrowska K, Nelson DC, et al. ClyJ is a novel pneumococcal chimeric lysin with a cysteine-and histidine-dependent amidohydrolase/peptidase catalytic domain. Antimicrob Agents Chemother. 2019;63(4): e02043-18 doi:10.1128/AAC.02043-18.
   Web of Science ®Google Scholar
• Yang H, Linden SB, Wang J, Yu J, Nelson DC, Wei H. A chimeolysin with extended-spectrum streptococcal host range found by an induced lysis-based rapid screening method. Sci Rep. 2015;5(1):1–12. doi:10.1038/srep17257.
   Google Scholar
• Xu J, Yang H, Bi Y, Li W, Wei H, Li Y. Activity of the chimeric lysin ClyR against common Gram-positive oral microbes and its anticaries efficacy in rat models. Viruses. Viruses. 2018;10(7):380. 10.3390/v10070380
   PubMed Web of Science ®Google Scholar
• Huang L, Luo D, Gondil VS, Gong Y, Jia M, Yan D, He J, Hu S, Yang H, Wei H. Construction and characterization of a chimeric lysin ClyV with improved bactericidal activity against Streptococcus agalactiae in vitro and in vivo. Appl Microbiol Biotechnol. 2020;104(4):1609–19. doi:10.1007/s00253-019-10325-z.
   PubMed Web of Science ®Google Scholar
• Jun SY, Jung GM, Yoon SJ, Choi Y-J, Koh WS, Moon KS, Kang SH. Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother. 2014;58(4):2084–88. doi:10.1128/AAC.02232-13.
   PubMed Web of Science ®Google Scholar
• Harhala M, Nelson D, Miernikiewicz P, Heselpoth R, Brzezicka B, Majewska J, Linden S, Shang X, Szymczak A, Lecion D, et al. Safety studies of pneumococcal endolysins Cpl-1 and Pal. Viruses Viruses. 2018;10(11):638. doi:10.3390/v10110638.
   PubMed Web of Science ®Google Scholar
• Corsini B, Díez-Martínez R, Aguinagalde L, González-Camacho F, García-Fernández E, Letrado P, García P, Yuste J. Chemotherapy with phage lysins reduces pneumococcal colonization of the respiratory tract. Antimicrob Agents Chemother. 2018;62(6):e02212–17. doi:10.1128/AAC.02212-17.
   PubMed Web of Science ®Google Scholar
• Wang Z, Ma J, Wang J, Yang D, Kong L, Fu Q, Cheng Y, Wang H, Yan Y, Sun J. Application of the phage lysin Ply5218 in the treatment of Streptococcus suis infection in piglets. Viruses. Viruses. 2019;11(8):715. doi:10.3390/v11080715.
   PubMed Web of Science ®Google Scholar
• Vázquez R, García P. Synergy between two chimeric lysins to kill Streptococcus pneumoniae. Front Microbiol. 2019;10:1251. doi:10.3389/fmicb.2019.01251.
   PubMed Web of Science ®Google Scholar
• Letrado P, Corsini B, Díez-Martínez R, Bustamante N, Yuste JE, García P. Bactericidal synergism between antibiotics and phage endolysin Cpl-711 to kill multidrug-resistant pneumococcus. Future Microbiol. 2018;13(11):1215–23. doi:10.2217/fmb-2018-0077.
   PubMed Web of Science ®Google Scholar
• Shah SU, Xiong YQ, Abdelhady W, Iwaz J, Pak Y, Schuch R, Cassino C, Lehoux D, Bayer AS. Effect of the lysin exebacase on cardiac vegetation progression in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis as determined by echocardiography. Antimicrob Agents Chemother. 2020;64(7): e00482-20. doi:10.1128/AAC.00482-20.
   Web of Science ®Google Scholar
• Karau MJ, Schmidt-Malan SM, Yan Q, Greenwood-Quaintance KE, Mandrekar J, Lehoux D, Schuch R, Cassino C, Patel R. Exebacase in addition to daptomycin is more active than daptomycin or exebacase alone in methicillin-resistant Staphylococcus aureus osteomyelitis in rats. Antimicrob Agents Chemother. 2019;63(10): e01235-19. doi:10.1128/AAC.01235-19.
   Web of Science ®Google Scholar
• Imanishi I, Uchiyama J, Tsukui T, Hisatsune J, Ide K, Matsuzaki S, Sugai M, Nishifuji K. Therapeutic potential of an endolysin derived from kayvirus S25-3 for staphylococcal impetigo. Viruses. 2019;11(9):769. doi:10.3390/v11090769.
   PubMed Web of Science ®Google Scholar
• Blasco L, Ambroa A, Trastoy R, Bleriot I, Moscoso M, Fernández-Garcia L, Perez-Nadales E, Fernández-Cuenca F, Torre-Cisneros J, Oteo-Iglesias J, et al. In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens. Sci Rep. 2020;10(1):1–12. doi:10.1038/s41598-020-64145-7.
   PubMed Web of Science ®Google Scholar
• Wu M, Hu K, Xie Y, Liu Y, Mu D, Guo H, Zhang Z, Zhang Y, Chang D, Shi Y. A novel phage PD-6A3, and its endolysin Ply6A3, with extended lytic activity against Acinetobacter baumannii. Front Microbiol. 2019;9:3302. doi:10.3389/fmicb.2018.03302.
   PubMed Web of Science ®Google Scholar
• Cheng M, Zhang L, Zhang H, Li X, Wang Y, Xia F, Wang B, Cai R, Guo Z, Zhang Y, et al. An ointment consisting of the phage lysin LysGH15 and apigenin for decolonization of methicillin-resistant Staphylococcus aureus from skin wounds. Viruses. 2018;10(5):244. doi:10.3390/v10050244.
   PubMed Web of Science ®Google Scholar
• Raz A, Serrano A, Hernandez A, Euler CW, Fischetti VA. Isolation of phage lysins that effectively kill Pseudomonas aeruginosa in mouse models of lung and skin infection. Antimicrob Agents Chemother. 2019;63(7): e00024-19. doi:10.1128/AAC.00024-19.
   Web of Science ®Google Scholar
• Gutiérrez D, Garrido V, Fernández L, Portilla S, Rodríguez A, Grilló MJ, García P. Phage lytic protein LysRODI prevents staphylococcal mastitis in mice. Front Microbiol. 2020;11:7. doi:10.3389/fmicb.2020.00007.
   PubMed Web of Science ®Google Scholar
• Wang F, Ji X, Li Q, Zhang G, Peng J, Hai J, Zhang Y, Ci B, Li H, Xiong Y, et al. Tspphg Lysin from the extremophilic thermus bacteriophage TSP4 as a potential antimicrobial agent against both gram-negative and gram-positive pathogenic bacteria. Viruses. 2020;12(2):192. doi:10.3390/v12020192.
   PubMed Web of Science ®Google Scholar
• Heselpoth RD, Euler CW, Schuch R, Fischetti VA. Lysocins: bioengineered antimicrobials that deliver lysins across the outer membrane of Gram-negative bacteria. Antimicrob Agents Chemother. 2019;63(6): e00342-19. doi:10.1128/AAC.00342-19.
   PubMed Web of Science ®Google Scholar
• Fraga AG, Trigo G, Murthy RK, Akhtar S, Hebbur M, Pacheco AR, Dominguez J, Silva-Gomes R, Gonçalves CM, Oliveira H, et al. Antimicrobial activity of Mycobacteriophage D29 Lysin B during Mycobacterium ulcerans infection. PLoS Negl Trop Dis. 2019;13(8): e0007113 doi:10.1371/journal.pntd.0007113.
   Web of Science ®Google Scholar
• Manohar P, Loh B, Elangovan N, Loganathan A, Nachimuthu R, Leptihn S. A multiwell-plate Caenorhabditis elegans assay for assessing the therapeutic potential of Bacteriophages against Clinical Pathogens. Microbiol Spectrum. 2022;10(1): e01393-21. doi:10.1128/spectrum.01393-21.
   PubMed Web of Science ®Google Scholar